First Tracks Biotherapeutics, Inc. (TRAX)

NASDAQ: TRAX · USD

$45.6

+0.26 (+0.6%)· Recorded snapshot

Market cap	1.9B
Net income (ttm)	-160.3M
EPS (ttm)	-$4.53
Shares out	42M
Volume	544,153

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -160.3M
EPS (ttm): -$4.53
Market cap: 1.9B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All TRAX indicators

Market & fundamental data

Available fields

140

Groups with data

Currency

USD

Showing 140 of 140 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002091349
Company name	First Tracks Biotherapeutics, Inc.
Country	United States
Country code	US
CUSIP number	337185102
Earnings date	2026-11-12
Earnings time	amc
Enterprise value	$1.8B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2025
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US3371851029
Last earnings date	2026-08-12
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.9B
Market cap category	Small-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$45.64
Price currency	USD
Sector	Healthcare
Stock price date	2026-10-28
Symbol	TRAX
U.S. state	California
Website	https://www.firsttracksbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-9.92%
FCF / EV yield	-7.17%
FCF yield	-6.55%
P/B ratio	9.51x
Price / tangible book value	11.19x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
ROCE	-99.35%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth quarters	1
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-55,000
Depreciation and amortization	$501,000
EBIT	$-169.6M
EBITDA	$-169.1M
EPS	$-4.53
FCF per share	$-2.95
Financing cash flow	$35.7M
Free cash flow	$-123.8M
Free cash flow minus SBC	$-160.5M
Investing cash flow	$211.7M
Net cash flow	$123.7M
Net income	$-160.3M
Operating cash flow minus SBC	$-160.5M
Operating income	$-169.6M
Stock-based compensation	$36.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$4.77
Debt / equity	0.03
Long-term assets	$5.4M
Long-term liabilities	$1.9M
Net cash (debt)	$163.7M
Net cash / market cap	8.66%
Net debt / equity	-0.97
Piotroski F-Score	1
Property, plant and equipment	$5.4M
Shareholders' equity	$168.8M
Tangible book value	$168.8M
Tangible book value per share	$4.77
Total assets	$183.1M
Total cash	$168M
Total debt	$4.3M
Total liabilities	$14.3M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$177.7M
Current liabilities	$12.4M
Current ratio	14.28
Net working capital	$-284,000
Quick ratio	13.91
Working capital	$165.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1D price change	0.57%
1M price change	32.16%
1M total return	32.16%
1W price change	10.28%
1W total return	10.28%
20-day SMA	$36.91
3M price change	8.23%
3M total return	8.23%
50-day SMA	$38.86
52-week high	$49.91
52-week high date	2026-08-11
52-week low	$14.72
52-week low date	2026-06-03
6M price change	151.33%
6M total return	151.33%
All-time high	$49.91
All-time high date	2026-08-11
All-time low	$14.72
All-time low date	2026-06-03
Average true range (ATR)	$3.12
Average volume	1.2M
Beta (1Y)	0.85
Change from 52-week high	-8.56%
Change from 52-week low	210.05%
Change from all-time high	-8.86%
Change from all-time low	209.04%
Change from open	1.09%
Day's gap	-0.51%
Dollar volume	$24.8M
High price	$46.10
Low price	$44.97
Monthly RSI	0
Open price	$45.15
Position in 52-week range	59.29%
Premarket change	-0.62%
Premarket close	$45.38
Premarket price	$45.10
Premarket volume	1.1K
Previous close	$45.38
Price vs 20-day SMA	23.24%
Price vs 50-day SMA	17.07%
Relative volume	0.45
RSI	67.7
Sharpe ratio	1.76
Sortino ratio	3.79
Volume	544.2K
Weekly RSI	67

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	26.2M
Float percentage	62.24%
Shares change (QoQ)	0.32%
Shares held by insiders	1.56%
Shares held by institutions	66.05%
Shares outstanding	42M
Short % of float	26.61%
Short % of shares	16.56%
Short ratio	7.1 days

Deeper analysis on TRAX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TRAX report

Is a complete TRAX research report available?

No complete published report is available for First Tracks Biotherapeutics, Inc. (TRAX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

First Tracks Biotherapeutics, Inc. (TRAX)

Price

Financial snapshot

Fair-value bridge

Latest news · TRAX

Valuation

Balance sheet

Trading

Next earnings

Sector percentile context

All TRAX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TRAX

Frequently asked questions